{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,6]],"date-time":"2026-11-06T06:16:52Z","timestamp":1793945812284,"version":"4.8.0"},"reference-count":46,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,9,1]],"date-time":"2025-09-01T00:00:00Z","timestamp":1756684800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/501100004735","name":"Natural Science Foundation of Hunan Province","doi-asserted-by":"publisher","award":["2023JJ40460"],"award-info":[{"award-number":["2023JJ40460"]}],"id":[{"id":"10.13039\/501100004735","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["82404692"],"award-info":[{"award-number":["82404692"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100013254","name":"National College Students Innovation and Entrepreneurship Training Program","doi-asserted-by":"publisher","award":["202412652001"],"award-info":[{"award-number":["202412652001"]}],"id":[{"id":"10.13039\/501100013254","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Journal of Medicinal Chemistry"],"published-print":{"date-parts":[[2025,9]]},"DOI":"10.1016\/j.ejmech.2025.117710","type":"journal-article","created":{"date-parts":[[2025,5,3]],"date-time":"2025-05-03T11:43:12Z","timestamp":1746272592000},"page":"117710","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":17,"special_numbering":"C","title":["Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders for the treatment of bladder cancer"],"prefix":"10.1016","volume":"293","author":[{"given":"Xiyue","family":"Yang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Linghui","family":"Wang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peiyu","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yueni","family":"Ning","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yusi","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yingying","family":"Xie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Congke","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lingli","family":"Mu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Cangcang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"1","key":"10.1016\/j.ejmech.2025.117710_bib1","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1038\/nrm.2017.83","article-title":"Ubiquitylation at the crossroads of development and disease","volume":"19","author":"Rape","year":"2018","journal-title":"Nat. Rev. Mol. Cell Biol."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117710_bib2","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s11658-020-00245-6","article-title":"Beyond K48 and K63: non-canonical protein ubiquitination","volume":"26","author":"Tracz","year":"2021","journal-title":"Cell. Mol. Biol. Lett."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117710_bib3","doi-asserted-by":"crossref","first-page":"579","DOI":"10.1038\/ncb3358","article-title":"The increasing complexity of the ubiquitin code","volume":"18","author":"Yau","year":"2016","journal-title":"Nat. Cell Biol."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117710_bib4","doi-asserted-by":"crossref","first-page":"181","DOI":"10.1038\/s41573-021-00371-6","article-title":"PROTAC targeted protein degraders: the past is prologue","volume":"21","author":"B\u00e9k\u00e9s","year":"2022","journal-title":"Nat. Rev. Drug Discov."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117710_bib5","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1016\/j.cell.2020.12.020","article-title":"The rise of molecular glues","volume":"184","author":"Schreiber","year":"2021","journal-title":"Cell"},{"issue":"5971","key":"10.1016\/j.ejmech.2025.117710_bib6","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1126\/science.1177319","article-title":"Identification of a primary target of thalidomide teratogenicity","volume":"327","author":"Ito","year":"2010","journal-title":"Science"},{"issue":"15","key":"10.1016\/j.ejmech.2025.117710_bib7","doi-asserted-by":"crossref","first-page":"8554","DOI":"10.1073\/pnas.141230798","article-title":"Protacs: chimeric molecules that target proteins to the Skp1-Cullin-F box complex for ubiquitination and degradation","volume":"98","author":"Sakamoto","year":"2001","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117710_bib8","doi-asserted-by":"crossref","first-page":"4465","DOI":"10.1021\/ja209924v","article-title":"Targeting the von Hippel-Lindau E3 ubiquitin ligase using small molecules to disrupt the VHL\/HIF-1\u03b1 interaction","volume":"134","author":"Buckley","year":"2012","journal-title":"J. Am. Chem. Soc."},{"issue":"10","key":"10.1016\/j.ejmech.2025.117710_bib9","doi-asserted-by":"crossref","first-page":"522","DOI":"10.1016\/j.neo.2020.07.002","article-title":"A highly potent PROTAC androgen receptor (AR) degrader ARD-61 effectively inhibits AR-positive breast cancer cell growth in vitro and tumor growth in vivo","volume":"22","author":"Zhao","year":"2020","journal-title":"Neoplasia"},{"issue":"3","key":"10.1016\/j.ejmech.2025.117710_bib10","doi-asserted-by":"crossref","first-page":"1420","DOI":"10.1021\/acs.jmedchem.8b01572","article-title":"Discovery of ERD-308 as a highly potent proteolysis targeting chimera (PROTAC) degrader of estrogen receptor (ER)","volume":"62","author":"Hu","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117710_bib11","article-title":"An overview of immune checkpoint inhibitor toxicities in bladder cancer","volume":"13","author":"Mavadia","year":"2024","journal-title":"Toxicol. Rep."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117710_bib12","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1080\/15569527.2022.2034842","article-title":"Adverse cutaneous toxicities by PD-1\/PD-L1 immune checkpoint inhibitors. Pathogenesis, treatment, and surveillance","volume":"41","author":"Bhardwaj","year":"2022","journal-title":"Cutan. Ocul. Toxicol."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117710_bib13","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.1001\/jamaoncol.2018.3923","article-title":"Fatal toxic effects associated with immune checkpoint inhibitors: a systematic review and meta-analysis","volume":"4","author":"Wang","year":"2018","journal-title":"JAMA Oncol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117710_bib14","doi-asserted-by":"crossref","first-page":"256","DOI":"10.1002\/cpt.3098","article-title":"Postmarketing safety of sacituzumab govitecan. A pharmacovigilance study based on the FDA adverse event reporting system","volume":"115","author":"Li","year":"2024","journal-title":"Clin. Pharmacol. Ther."},{"key":"10.1016\/j.ejmech.2025.117710_bib15","doi-asserted-by":"crossref","first-page":"1503154","DOI":"10.3389\/fphar.2024.1503154","article-title":"Characterizing ADRs of enfortumab vedotin and erdafitinib in bladder cancer treatment: a descriptive analysis from WHO-VigiAccess","volume":"15","author":"Huang","year":"2024","journal-title":"Front. Pharmacol."},{"key":"10.1016\/j.ejmech.2025.117710_bib16","doi-asserted-by":"crossref","DOI":"10.1016\/j.bioorg.2022.106327","article-title":"Design, synthesis, and biological evaluation of novel protopanoxadiol derivatives based PROTACs technology for the treatment of lung cancer","volume":"131","author":"Wang","year":"2023","journal-title":"Bioorg. Chem."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117710_bib17","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1021\/np200906s","article-title":"Natural products as sources of new drugs over the 30 years from 1981 to 2010","volume":"75","author":"Newman","year":"2012","journal-title":"J. Nat. Prod."},{"key":"10.1016\/j.ejmech.2025.117710_bib18","doi-asserted-by":"crossref","first-page":"219","DOI":"10.1016\/j.jare.2023.10.014","article-title":"PROTAC derivatization of natural products for target identification and drug discovery. Design of evodiamine-based PROTACs as novel REXO4 degraders","volume":"63","author":"Chen","year":"2024","journal-title":"J. Adv. Res."},{"issue":"17","key":"10.1016\/j.ejmech.2025.117710_bib19","doi-asserted-by":"crossref","first-page":"7643","DOI":"10.1021\/acs.jmedchem.9b00794","article-title":"Discovery of evobrutinib: an oral, potent, and highly selective, covalent Bruton's tyrosine kinase (BTK) inhibitor for the treatment of immunological diseases","volume":"62","author":"Caldwell","year":"2019","journal-title":"J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117710_bib20","doi-asserted-by":"crossref","first-page":"48","DOI":"10.1186\/s13020-019-0270-9","article-title":"Naturally occurring anti-cancer compounds: shining from Chinese herbal medicine","volume":"14","author":"Luo","year":"2019","journal-title":"Chin. Med."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117710_bib21","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1139\/bcb-2021-0275","article-title":"Artesunate inhibits proliferation, migration, and invasion of thyroid cancer cells by regulating the PI3K\/AKT\/FKHR pathway","volume":"100","author":"Xu","year":"2022","journal-title":"Biochem. Cell. Biol."},{"key":"10.1016\/j.ejmech.2025.117710_bib22","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1016\/j.ejmech.2016.08.015","article-title":"Synthesis and cytotoxicity of novel artemisinin derivatives containing sulfur atoms","volume":"123","author":"Xu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"key":"10.1016\/j.ejmech.2025.117710_bib23","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1016\/j.ejmech.2015.11.003","article-title":"Synthesis and in vitro antitumor evaluation of dihydroartemisinin-cinnamic acid ester derivatives","volume":"107","author":"Xu","year":"2016","journal-title":"Eur. J. Med. Chem."},{"issue":"16","key":"10.1016\/j.ejmech.2025.117710_bib24","doi-asserted-by":"crossref","first-page":"2472","DOI":"10.3390\/cells11162472","article-title":"Artesunate inhibits the cell growth in colorectal cancer by promoting ROS-dependent cell senescence and autophagy","volume":"11","author":"Huang","year":"2022","journal-title":"Cells"},{"key":"10.1016\/j.ejmech.2025.117710_bib25","doi-asserted-by":"crossref","DOI":"10.1016\/j.cbi.2020.109273","article-title":"Artesunate induces autophagy dependent apoptosis through upregulating ROS and activating AMPK-mTOR-ULK1 axis in human bladder cancer cells","volume":"331","author":"Zhou","year":"2020","journal-title":"Chem. Biol. Interact."},{"issue":"12","key":"10.1016\/j.ejmech.2025.117710_bib26","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.3390\/cells9122643","article-title":"Artesunate impairs growth in cisplatin-resistant bladder cancer cells by cell cycle arrest, apoptosis and autophagy induction","volume":"9","author":"Zhao","year":"2020","journal-title":"Cells"},{"issue":"8","key":"10.1016\/j.ejmech.2025.117710_bib27","doi-asserted-by":"crossref","first-page":"14298","DOI":"10.3390\/ijms150814298","article-title":"Artesunate induces apoptosis of bladder cancer cells by miR-16 regulation of COX-2 expression","volume":"15","author":"Zuo","year":"2014","journal-title":"Int. J. Mol. Sci."},{"issue":"14","key":"10.1016\/j.ejmech.2025.117710_bib28","doi-asserted-by":"crossref","first-page":"4432","DOI":"10.1016\/j.bmc.2013.04.059","article-title":"Novel artemisinin derivatives with potential usefulness against liver\/colon cancer and viral hepatitis","volume":"21","author":"Blazquez","year":"2013","journal-title":"Bioorg. Med. Chem."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117710_bib29","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1080\/13543776.2021.1840553","article-title":"The therapeutic potential of PROTACs","volume":"31","author":"Benowitz","year":"2021","journal-title":"Expert Opin. Ther. Pat."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117710_bib30","doi-asserted-by":"crossref","first-page":"354","DOI":"10.1210\/endrev\/bnab002","article-title":"Hormonal therapy for prostate cancer","volume":"42","author":"Desai","year":"2021","journal-title":"Endocr. Rev."},{"key":"10.1016\/j.ejmech.2025.117710_bib31","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejps.2023.106624","article-title":"Proteolysis targeting chimeras (PROTACs) based on celastrol induce multiple protein degradation for triple-negative breast cancer treatment","volume":"192","author":"Gan","year":"2024","journal-title":"Eur. J. Pharm. Sci."},{"key":"10.1016\/j.ejmech.2025.117710_bib32","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1016\/j.redox.2016.12.010","article-title":"Nrf2 inhibition reverses the resistance of cisplatin-resistant head and neck cancer cells to artesunate-induced ferroptosis","volume":"11","author":"Roh","year":"2017","journal-title":"Redox Biol."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117710_bib33","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1038\/s41401-020-0478-3","article-title":"Artesunate synergizes with sorafenib to induce ferroptosis in hepatocellular carcinoma","volume":"42","author":"Li","year":"2021","journal-title":"Acta Pharmacol. Sin."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117710_bib34","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jphs.2022.01.007","article-title":"Artesunate induces ferroptosis via modulation of p38 and ERK signaling pathway in glioblastoma cells","volume":"148","author":"Song","year":"2022","journal-title":"J. Pharmacol. Sci."},{"issue":"2","key":"10.1016\/j.ejmech.2025.117710_bib35","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1038\/s41422-020-00441-1","article-title":"Ferroptosis: molecular mechanisms and health implications","volume":"31","author":"Tang","year":"2021","journal-title":"Cell Res."},{"issue":"1","key":"10.1016\/j.ejmech.2025.117710_bib36","doi-asserted-by":"crossref","first-page":"47","DOI":"10.1186\/s12943-022-01530-y","article-title":"Ferroptosis in cancer therapy: a novel approach to reversing drug resistance","volume":"21","author":"Zhang","year":"2022","journal-title":"Mol. Cancer"},{"issue":"6","key":"10.1016\/j.ejmech.2025.117710_bib37","doi-asserted-by":"crossref","first-page":"830","DOI":"10.1016\/j.ccell.2019.04.002","article-title":"Targeting ferroptosis to iron out cancer","volume":"35","author":"Hassannia","year":"2019","journal-title":"Cancer Cell"},{"key":"10.1016\/j.ejmech.2025.117710_bib38","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2022.113953","article-title":"Ginkgolide B alleviates oxidative stress and ferroptosis by inhibiting GPX4 ubiquitination to improve diabetic nephropathy","volume":"156","author":"Chen","year":"2022","journal-title":"Biomed. Pharmacother."},{"issue":"3","key":"10.1016\/j.ejmech.2025.117710_bib39","article-title":"GPX4: the hub of lipid oxidation, ferroptosis, disease and treatment","volume":"1878","author":"Liu","year":"2023","journal-title":"Biochim. Biophys. Acta Rev. Canc"},{"issue":"18","key":"10.1016\/j.ejmech.2025.117710_bib40","doi-asserted-by":"crossref","first-page":"2210","DOI":"10.1097\/CM9.0000000000002675","article-title":"Isoliquiritigenin induces HMOX1 and GPX4-mediated ferroptosis in gallbladder cancer cells","volume":"136","author":"Wang","year":"2023","journal-title":"Chin. Med. J. (Engl. Ed.)"},{"issue":"12","key":"10.1016\/j.ejmech.2025.117710_bib41","doi-asserted-by":"crossref","first-page":"1710","DOI":"10.3390\/ph16121710","article-title":"Compensative resistance to erastin-induced ferroptosis in GPX4 knock-out mutants in HCT116 cell lines","volume":"16","author":"Adamiec-Organisciok","year":"2023","journal-title":"Pharmaceuticals"},{"key":"10.1016\/j.ejmech.2025.117710_bib42","doi-asserted-by":"crossref","DOI":"10.1016\/j.bmcl.2021.127912","article-title":"Synthesis and biological activities of novel mitochondria-targeted artemisinin ester derivatives","volume":"39","author":"Xu","year":"2021","journal-title":"Bioorg. Med. Chem. Lett"},{"issue":"2","key":"10.1016\/j.ejmech.2025.117710_bib43","doi-asserted-by":"crossref","first-page":"117","DOI":"10.2174\/1566523219666190628152137","article-title":"The relationship between ferroptosis and tumors: a novel landscape for therapeutic approach","volume":"19","author":"Xia","year":"2019","journal-title":"Curr. Gene Ther."},{"issue":"7","key":"10.1016\/j.ejmech.2025.117710_bib44","doi-asserted-by":"crossref","DOI":"10.1016\/j.heliyon.2024.e28584","article-title":"Artesunate induces ferroptosis by regulating MT1G and has an additive effect with doxorubicin in diffuse large B-cell lymphoma cells","volume":"10","author":"Xiong","year":"2024","journal-title":"Heliyon"},{"key":"10.1016\/j.ejmech.2025.117710_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.ejmech.2024.116670","article-title":"Ferroptosis-inducing compounds synergize with docetaxel to overcome chemoresistance in docetaxel-resistant non-small cell lung cancer cells","volume":"276","author":"Huang","year":"2024","journal-title":"Eur. J. Med. Chem."},{"issue":"6","key":"10.1016\/j.ejmech.2025.117710_bib46","doi-asserted-by":"crossref","first-page":"356","DOI":"10.1038\/s41419-023-05868-z","article-title":"HNF4A-BAP31-VDAC1 axis synchronously regulates cell proliferation and ferroptosis in gastric cancer","volume":"14","author":"Zhou","year":"2023","journal-title":"Cell Death Dis."}],"updated-by":[{"DOI":"10.1016\/j.ejmech.2025.118140","type":"erratum","label":"Erratum","source":"publisher","updated":{"date-parts":[[2025,12,15]],"date-time":"2025-12-15T00:00:00Z","timestamp":1765756800000}}],"container-title":["European Journal of Medicinal Chemistry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004751?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0223523425004751?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T06:08:05Z","timestamp":1777529285000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0223523425004751"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,9]]},"references-count":46,"alternative-id":["S0223523425004751"],"URL":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117710","relation":{},"ISSN":["0223-5234"],"issn-type":[{"value":"0223-5234","type":"print"}],"subject":[],"published":{"date-parts":[[2025,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Discovery of Artesunate (ARS) PROTACs as GPX4 protein degraders for the treatment of bladder cancer","name":"articletitle","label":"Article Title"},{"value":"European Journal of Medicinal Chemistry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ejmech.2025.117710","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier Masson SAS. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"117710"}}